J B Bussel
About
In The Last Decade
J B Bussel
21 papers receiving 912 citations
Peers
Comparison fields: 5 of 69
- Hematology 748
- Genetics 262
- Immunology 249
- Surgery 129
- Pulmonary and Respiratory Medicine 82
Countries citing papers authored by J B Bussel
This map shows the geographic impact of J B Bussel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J B Bussel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J B Bussel more than expected).
Fields of papers citing papers by J B Bussel
This network shows the impact of papers produced by J B Bussel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J B Bussel. The network helps show where J B Bussel may publish in the future.
Co-authorship network of co-authors of J B Bussel
This figure shows the co-authorship network connecting the top 25 collaborators of J B Bussel. A scholar is included among the top collaborators of J B Bussel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J B Bussel. J B Bussel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia (vol 384, pg 2254, 2021) | 2 |
| 2 | EFFICACY AND SAFETY OF REPEATED INTERMITTENT TREATMENT WITH ELTROMBOPAG IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) | 2 |
| 3 | Eltrombopag, an oral platelet growth factor, for treatment of chronic immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial | 1 |
| 4 | 1 | |
| 5 | Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. | 28 |
| 6 | Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura. | 20 |
| 7 | 18 | |
| 8 | 15 | |
| 9 | Type II congenital dyserythropoietic anemia in a patient with ectodermal dysplasia. Distinction from dyskeratosis congenita. | 2 |
| 10 | Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. The Working Party on Neonatal Immune Thrombocytopenia of the Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the ISTH. | 65 |
| 11 | 5 | |
| 12 | 148 | |
| 13 | 2 | |
| 14 | 26 | |
| 15 | 40 | |
| 16 | 30 | |
| 17 | 231 | |
| 18 | 58 | |
| 19 | 168 | |
| 20 | Transient appearance of the lupus anticoagulant in three family members sharing the A11B35DR4 haplotype. | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.